The first Japanese case of leukodystrophy with ovarian failure arising from novel compound heterozygous AARS2 mutations by Hamatani, Mio et al.
Title The first Japanese case of leukodystrophy with ovarian failurearising from novel compound heterozygous AARS2 mutations
Author(s)
Hamatani, Mio; Jingami, Naoto; Tsurusaki, Yoshinori;
Shimada, Shino; Shimojima, Keiko; Asada-Utsugi, Megumi;
Yo hinaga, Kenji; Uemura, Norihito; Yamashita, Hirofumi;
Uemura, Kengo; Takahashi, Ryosuke; Matsumoto, Naomichi;
Yamamoto, Toshiyuki




This is the accepted version of the article, which has been
published in final form at
http://dx.doi.org/10.1038/jhg.2016.64; The full-text file will be
made open to the public on 02 December 2016 in accordance
with publisher's 'Terms and Conditions for Self-Archiving';






Mio Hamatani #1 
Title: The First Japanese Case of Leukodystrophy with Ovarian Failure Arising from Novel 1 



































Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan 9 
2
Department of Human Genetics, Yokohama City University Graduate School of Medicine, 10 
Yokohama, Japan 11 
3
Tokyo Women's Medical University Institute for Integrated Medical Sciences, Tokyo, Japan 12 
4
Department of Neurology, Ishiki Hospital, Kagoshima, Japan 13 
*These authors contributed equally to this work. 14 
 15 
Correspondence: Dr. H. Yamashita, Department of Neurology, Kyoto University Graduate 16 
School of Medicine, 54 Shogoin-Kawaharacho, Sakyoku, Kyoto 606-8507, Japan. 17 
Phone: +81-75-751-3771, Fax: +81-75-751-3265,  18 
E-mail: hirofumi@kuhp.kyoto-u.ac.jp 19 
Or Dr. K. Uemura, Department of Neurology, Ishiki Hospital, 2-4-15 Shimoishiki, Kagoshima 20 
890-0005, Japan. 21 
Phone: +81-99-220-4645, Fax: +81-99-220-4648,  22 
E-mail: ueken@kuhp.kyoto-u.ac.jp 23 
 24 
Running title: The First Japanese Case of AARS2 Mutation 25 
 26 
Abbreviations: AARS2; alanyl-tRNA synthetase 2 27 
 28 
Type of article: Short communication 29 
 30 
Number of total pages: 14 31 
Number of words (including the abstract): 1268 32 
Number of words (abstract): 98 33 
Number of references: 17 34 
Number of figures: 3 35 
Number of tables: 0 36 
Mio Hamatani #2 
Supplementary information: 1, Microsoft Word documents (.doc)  1 
Mio Hamatani #3 
Abstract 1 
Even now, only a portion of leukodystrophy patients are correctly diagnosed, though 2 
various causative genes have been identified. In the present report, we describe a case of 3 
adult-onset leukodystrophy in a woman with ovarian failure. By whole exome sequencing, a 4 
compound heterozygous mutation consisting of NM_020745.3 (AARS2_v001):c.1145C>A and 5 
NM_020745.3 (AARS2_v001):c.2255+1G>A was identified. Neither of the mutations has been 6 
previously reported, and this is the first report of AARS2 mutation in Asia. We anticipate that 7 
further studies of the molecular basis of leukodystrophy will provide insight into its 8 
pathogenesis and hopefully lead to sophisticated diagnostic and treatment strategies. 9 
Key words: AARS2/compound heterozygous mutation/leukodystrophy/ovarian failure 10 
  11 
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Introduction 1 
Leukodystrophy is a syndrome with progressive white matter degeneration. Its pathogenic 2 
background and clinical presentation are variable. Genetic rather than environmental factors are 3 
associated with its variablity.
1
 More than a hundred subtypes of leukodystrophy have been 4 
reported, and many causative genes have been identified.
2
 However, the heterogeneity and 5 
complexity of leukodystrophy make a definitive diagnosis difficult. Indeed, only half of 6 
leukodystrophy patients receive a specific diagnosis.
3 
7 
Here, we report a Japanese woman presenting with adult-onset leukodystrophy and ovarian 8 
failure in her thirties. By whole exome sequencing (WES), we detected novel compound 9 
heterozygous mutations in alanyl-transfer RNA (tRNA) synthetase 2 (AARS2) (OMIM 10 
*612035). 11 
 12 
Case report 13 
A 31-year-old Japanese woman first visited our hospital in 2010. She was born healthy 14 
with a normal delivery to non-consanguineous parents. She developed normally and graduated 15 
from college. She worked until she was 30 years old, when she suddenly quit her job and had 16 
reduced interactions with her surroundings. She developed cognitive decline and began 17 
abnormal behaviors (e.g., buying the same thing on consecutive days). She had difficulty using 18 
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her left limbs, and she tended to lean to the left while sitting. She became totally incontinent. No 1 
similar symptoms occurred in her parents or her older sister.  2 
A general examination at age 33 revealed secondary amenorrhea, although she had normal 3 
menstrual cycles until then with normal secondary sexual characteristics. The unelevated 4 
gonadotropin level indicated the impairment of reactive gonadotropin release by hypothalamus 5 
and pituitary, suggesting the secondary ovarian failure. She also had generalized atopic 6 
dermatitis. 7 
Neurological examination revealed significant decline in frontal lobe function. The patient 8 
had a Mini-Mental State Examination score of 19/30 and a Frontal Assessment Battery score of 9 
4/18. Left hand ideomotor apraxia, hyperreflexia, and rigidity of neck and limbs were observed 10 
more on the left side. At the most recent examination at age 38, the patient was aphasic and 11 
almost bedridden. 12 
Brain magnetic resonance imaging (MRI) showed diffuse cerebral white matter 13 
abnormalities without gadolinium enhancement. Patchy, diffusion-restricted areas were present 14 
in the abnormal white matter. Thinning of corpus callosum was also observed (Figure 1). 15 
Cardiac ultrasound and electrocardiography showed no abnormalities. 16 
Laboratory workups including plasma/cerebrospinal fluid lactate, serum arylsulfatase A, 17 
galactocerebrosidase, very long chain fatty acids, and cholestanol were within normal ranges. 18 
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Gene analyses of colony stimulating factor 1 receptor (CSF1R) and eukaryotic translation 1 
initiation factor 2B (EIF2B) were normal. We performed WES on genomic DNA. 2 
 3 
Genetic analysis 4 
Genetic analysis by WES was approved by the Tokyo Women's Medical University Ethical 5 
Committee, and written informed consent was obtained from the patient’s parents. DNA 6 
samples from the patient and her parents were analyzed by WES, as previously described.
4
 7 
Detailed methods of WES and prioritization of variants are described in the supplementary 8 
information. 9 
We focused on de novo and recessive mutations. We found novel compound heterozygous 10 
mutations in AARS2, NM_020745.3 (AARS2_v001):c.1145C>A and NM_020745.3 11 
(AARS2_v001):c.2255+1G>A. These were the missense mutation (p.T382K) and the splice-site 12 
mutation, respectively. These two mutations were not registered in the dbSNP137, NHLBI-ESP 13 
6500, HGVD, or our in-house 575 Japanese control exome databases. Sanger sequencing 14 
confirmed that the mutations were transmitted maternally and paternally, respectively (Figure 2), 15 
and the in silico analysis for the pathogenicities is described in the supplementary information. 16 
Next, we performed messenger RNA (mRNA) analysis around the segments harboring 17 
each mutation (Figure 3a). We could not detect any aberrantly-spliced mRNA caused by the 18 
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splice-site mutation (Figure 3b). Direct sequence analysis of cDNA revealed that the patient was 1 
heterozygous at the locus for c.1145, and the sequence around c.2255 was normal without any 2 
aberrant insertion or truncation (Figure 3c). 3 
 4 
Discussion 5 
The causative gene in a Japanese leukodystrophy patient with ovarian failure was identified 6 
as a compound heterozygous AARS2 mutation.  7 
We initially considered the patient’s diagnosis as hereditary diffuse leukoencephalopathy 8 
with axonal spheroids, which is most prevalent in women in their 30s and 40s and frequently 9 
includes corpus callosum thinning.
5-7
 We also suspected vanishing white matter disease, which 10 
includes ovarian failure as one of its features.
8-11
 However, no mutation in causative genes for 11 
these diseases were identified. 12 
Therefore, we performed a comprehensive genetic workup and, by use of WES, compound 13 
heterozygous mutations, c.1145C>A (p.T382K) and c.2255+1G>A, were detected. These 14 
mutations were inherited as an autosomal recessive trait. Both mutations were novel and 15 
predicted as pathogenic in silico. In the analysis of the patient’s mRNA, we could not detect any 16 
misspliced mature mRNA caused by the splice-site mutation, c.2255+1G>A. However, it is 17 
predicted that the mutation introduced a premature stop codon when the splicing at the 18 
Mio Hamatani #8 
exon16-intron16 boundary failed (Figure 3a). Then this transcript would be a target for the 1 
nonsense-mediated mRNA decay and should be degraded. 2 
AARS2 encodes mitochondrial alanyl-tRNA synthetase, an enzyme that charges a specific 3 
tRNA with its cognate amino acid, alanine. AARS2 mutation was recently shown to cause 4 
mitochondrial dysfunction and reported in 6 patients with adult-onset leukodystrophy
12
. In that 5 
report, two specific clinical phenotypes were described: characteristic MRI features and ovarian 6 
failure. Common MRI features are striking white matter tract involvement and presence of spots 7 
of restricted diffusion in the cerebral white matter. Corpus callosum thinning and the strip of 8 
signal abnormality in the splenium were also seen. Ovarian failure was present in all of the 9 
previously reported 5 female cases; 1 case had secondary amenorrhea like the present patient, 10 
and 4 cases had primary amenorrhea. 11 
AARS2 mutations have another subtype, severe infantile cardiomyopathy with early fatal 12 
outcome.
13-15
 In contrast to this infantile subtype, the later-onset subtype, which includes the 13 
present case, has no signs of cardiomyopathy. Therefore, the question arises why AARS2 14 
mutations cause two very different subtypes with dissimilar tissue involvement. In 2015, Euro et 15 
al. gave the elegant explanation for the phenomenon.
16
 AARS2 is unique among the human 16 
mitochondrial aminoacyl-tRNA synthetases because it contains an editing domain for 17 
deacylating mischarged tRNAs in addition to the aminoacylation domain. All patients with 18 
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infantile-onset cardiomyopathy had the c.1774C>T (p.R592W) mutation located in the editing 1 
domain in at least one allele, which severely compromises aminoacylation. On the other hand, 2 
none of the missense mutations in adult-onset leukodystrophy patients were in the editing 3 
domain, while at least one missense mutation was in the aminoacylation domain, leading to 4 
relatively partial reduction in aminoacylation activity. The location of the compound 5 
heterozygous mutations in the present case is consistent with the theory. 6 
In conclusion, we describe a Japanese woman with novel compound heterozygous 7 
mutations in AARS2, the first report of leukodystrophy caused by AARS2 mutations in Asia. 8 
This is also the subsequent report after the first description in 2014 for 6 adult-onset 9 
leukodystrophy patients by AARS2 mutations. All reported cases including the present case are 10 
apparently sporadic without family history and caused by compound heterozygous mutations, 11 
making the correct diagnosis very difficult. Therefore, if you will notice the characteristic MRI 12 
findings and, especially in female, the existence of ovarian failure, you should examine the 13 
AARS2 gene. 14 
Further identification of disease-causing mutations with detailed clinical descriptions 15 
including MRI and menstrual history will provide diagnostic clues, and will contribute to 16 
unraveling the disease mechanism, and hopefully lead to the development of treatment 17 
strategies. 18 
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Titles and legends to figures 1 
Figure 1. Brain MRI of the patient at age 33 2 
The fluid attenuated inversion recovery (FLAIR) images show periventricular white matter 3 
abnormalities predominant at the parietal and frontal area, which revealed low signal lesions in 4 
the T1-weighted image (arrows in images a, b and c). The diffusion-weighted image shows 5 
patchy areas of restricted diffusion in the abnormal white matter, which are confirmed by low 6 
signal of the corresponding areas on the apparent diffusion coefficient map (arrows in image d, 7 
e and f). The sagittal FLAIR image shows thinned corpus callosum, especially in the splenium 8 
(arrow in image g) and affected white matter structures in a tract-like manner (arrow in image h). 9 
The MR angiography showed no stenosis of the major vessels (image i). 10 
 11 
Figure 2. Sanger sequencing of the patient and her parents 12 
The mutations were confirmed by Sanger sequencing. c.1145C>A (p.T382K) was transmitted 13 
maternally, and c.2255+1G>A was transmitted paternally. 14 
 15 
Figure 3. mRNA analysis 16 
(a) Genomic structure of AARS2 was illustrated. Arrowheads indicate primer pairs. Triplets 17 
under bases indicate reading frames and, assuming that the mutation c.2255+1G>A causes 18 
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splicing error, a premature stop codon will appear just afterwards (blue). (b) Image of PCR 1 
products of cDNA including each mutation (PCR1 and PCR2). (c) Direct sequence analysis of 2 
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Whole exome sequencing and in silico analysis for the pathogenicities 
DNA samples from the patient and her parents were analyzed by whole exome sequencing (WES) 
as previously described. Genomic DNA was captured by using the SureSelect Human All Exon v5 
(50Mb) Kit (Agilent Technologies, Santa Clara, CA). Captured DNA was sequenced on a 
HiSeq2500 (Illumina, San Diego, CA) with 101 bp paired-end reads and 7 bp index reads. The 
mean read depth against RefSeq coding sequence (CDS) was 38.18–158.75 reads with 74.6–95.5% 
of CDS being covered by 20 or more reads. Image analysis and base calling were performed by 
sequence control software real-time analysis and CASAVA software (v1.8) (Illumina). The quality 
controlled reads were mapped to the human reference genome (UCSC hg19, NCBI build 37.1) by 
using Novoalign (v3.00.02). After the removal of PCR duplication by using Picard (v1.55), single 
nucleotide variants (SNVs) and short insertions and deletions (Indels) were identified by using 
Genome Analysis Toolkit (GATK) (v1.6-5) and annotated by using ANNOVAR (2013 jun). 
Out of all variants within exons and regions ±30 bp from the exon-intron boundaries, those 
registered common single nucleotide polymorphisms (SNP) with minor allele frequency of  
>1% in dbSNP137, and common SNP containing six or more individuals in our in-house database 
(exome data from 575 Japanese individuals), and synonymous variants were all removed. The 
variants were confirmed by Sanger sequencing with an ABI PRISM 3500xl or ABI3130xl 
autosequencer (Life Technologies, Carlsbad, CA). 
We focused on de novo and recessive mutations, then we found novel compound heterozygous 
mutations in AARS2.The missense mutation (p.T382K) was predicted as deleterious (0.01) by SIFT 
(http://sift.jcvi.org/), possibly damaging (0.712) by Polyphen-2 
(http://genetics.bwh.harvard.edu/pph2/). The splice-site mutation (c.2255+1G>A) was predicted as 
abolishing a donor site by BDGP (http://www.fruitfly.org/seq_tools/splice.html) and NetGene2 
(http://www.cbs.dtu.dk/services/NetGene2/), and as altering the donor site and most probably 
affecting splicing (86.07 to 59.23) by Human Splicing Finder (http://www.umd.be/HSF3/). 
 
mRNA analysis 
Total RNA was extracted from the white blood cells of the patient and a healthy control by using 
QIAamp RNA Blood Mini and RNase-Free DNase set (QIAGEN). cDNA was synthesized with 
random primers by use of First-Strand cDNA Synthesis Kit (GE Healthcare). cDNA of AARS2 was 
amplified by polymerase chain reaction (PCR) using the primer pairs, 
5’-GCCGCCTTTCTGAACTTCTT-3’, and 5’-GGCAGCTTCCAGGTCAGTAG-3’. Then, 
segments harboring c.1145C>A or c.2255+1G>A were amplified by nested-PCR using the primer 
pairs, 5’-CTGCAAGGCAAACACTCCAC-3’ and 5’-CCAGGTCTCCACACAGTGAC-3’, 
5’-AGGGCTCCCATCTCAATCCT-3’ and 5’-GCTGCAGCATCTTCACTGTG-3’, respectively 
(Figure 3a). 
